Inovio Pharmaceuticals Inc Stock Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Financials (USD)
Sales 2024 * | 348K | Sales 2025 * | 20.24M | Capitalization | 293M |
---|---|---|---|---|---|
Net income 2024 * | -121M | Net income 2025 * | -111M | EV / Sales 2024 * | 842 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.5 x |
P/E ratio 2024 * |
-2.56
x | P/E ratio 2025 * |
-3.53
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |